Best of ASCO - 2014 Annual Meeting



Advanced Disease

Gastrointestinal (Colorectal) Cancer

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
5-fluorouracil plus bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): An investigator-initiated, open-label, single-arm, multicentre, phase 2 study.

Nicolas Isambert


A meta-analysis exploring the role of PET and PET-CT in the management of potentially resectable colorectal cancer liver metastasis.

Julian Daza Vargas


A novel biomarker combination and its association with resistance to chemotherapy combinations with bevacizumab: First results of the PERMAD trial.

Thomas Seufferlein


A phase I expansion study of trifluridine and tipiracil (FTD/TPI) in combination with irinotecan (IRI) and bevacizumab (BEV) in patients with metastatic colorectal cancer (mCRC).

Anna M. Varghese


A phase I/II study of nintedanib and capecitabine in refractory metastatic colorectal cancer.

Patrick McKay Boland


A phase I/II trial of cabozantinib (C) with or without panitumumab (P) in patients (pts) with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Clinical outcomes in pts with MET amplification (amp) detected in blood.

Jingquan Jia


A pilot study of omalizumab to reduce the incidence of oxaliplatin-induced hypersensitivity reaction (HSR): An interim analysis.

Stacey Stein


A prospective multicenter observational study of bevacizumab for the treatment of metastatic colorectal cancer in Chinese patients (Obtain study).

Fenghua Wang


A prospective phase II study of raltitrexed combined with S-1 as salvage treatment for patients with metastatic colorectal cancer after failure of standard chemotherapy.

Mingzhu Huang


A randomized phase II study of perioperative chemotherapy plus bevacizumab versus postoperative chemotherapy plus bevacizumab inpatients with upfront resectable hepatic colorectal metastases (APPROACH).

You Jin Chun


A randomized phase II study of trastuzumab and pertuzumab (TP) compared to cetuximab and irinotecan (CETIRI) in advanced/metastatic colorectal cancer (mCRC) with HER2 amplification: S1613.

Kanwal Pratap Singh Raghav


A validation study of stratification by the 55-gene classifier for assessing recurrence risk in stage II colon cancer: The 55 STAR study (UMIN23879).

Shigeki Yamaguchi


ABT-165 plus FOLFIRI vs bevacizumab (bev) plus FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bev.

Zev A. Wainberg


Actionable fusions in colorectal cancer using a cell-free circulating tumor DNA (ctDNA) assay.

Katherine Clifton


Adding oxaliplatin (OX) to neoadjuvant therapy of locally advanced rectal cancer (LARC): Still a promising option?

Wojciech Rogowski


Analysis of liquid biopsies from metastatic colorectal carcinoma (mCRC) patients (pts) enrolled in the ERMES clinical trial.

Nicola Normanno


Anti-EGFR resistant clones decay exponentially after progression: Implications for anti-EGFR rechallenge.

Christine Megerdichian Parseghian


Apatinib as a salvage treatment for refractory metastatic colorectal cancer.

Xiaofeng Chen


APOLLON: A phase I/II study of panitumumab combined with TAS-102 in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC).

Yasutoshi Kuboki


Association between genotypes, clinical scores and survival outcome in metastatic colorectal cancer.

Moreno Reinaldo


Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Results of the safety run-in phase of the phase II AVETUX trial (AIO-KRK-0216).

Alexander Stein


Bevacizumab (B) + bi-weekly capecitabine (C) and oxaliplatin (O) (XELOX2) or FOLFOX4 in first-line treatment of metastatic colorectal cancer (mCRC): Final results of a multicenter randomized phase II trial of the Gruppo Oncologico dell’Italia Meridionale (GOIM protocol 2802).

Evaristo Maiello


BRAF (V600E) mutant metastatic colorectal cancer: What is the role of the antiangiogenic therapy in a real-world setting?

Nieves Martinez Lago


Can machine learning predict resecability of a peritoneal carcinomatosis.

Alexandre Maubert


Change in CEA as an early predictor of progression to first-line systemic therapy in metastatic colorectal cancer.

Pat Gulhati


Circulating tumor DNA (ctDNA) as an early marker to monitor clinical benefit of regorafenib and TAS-102 in patients with metastatic colorectal cancer (mCRC).

Allan Andresson Lima Pereira


Circulating vitamin D during neoadjuvant therapy in high-risk rectal cancer.

Hanna Abrahamsson


Clinical and molecular determinants of extrahepatic disease progression (ePD) in initially unresectable, liver limited metastatic colorectal cancer (mCRC).

Elena Ongaro


Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study (NRG- GI004/SWOG-S1610): A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer.

James J. Lee


Comparison of mismatch repair status between primary and matched metastatic sites in patients with colorectal cancer.

Wen-Zhuo He


Correlation of measurements of tumor heterogeneity based on next-generation sequencing (NGS) of circulating tumor DNA (ctDNA) with clinical outcomes in STEAM, a prospective, randomized, multicenter study in metastatic colorectal cancer (mCRC).

Stephanie Yaung


Correlation of MLLT3 deletion mutation with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients identified by whole-exome sequencing.

Rong-xin Zhang


Dissecting the prognostic role of sidedness in metastatic colon cancer (mCC): Retrospective analysis of the impact of chemotherapy sequence (CTS) and primary site resection (PTR) in a health care system.

Feng-Che Kuan


Distinct impacts of KRAS, NRAS and BRAF mutations on survival of patients with metastatic colorectal cancer.

Yucai Wang


Dynamic monitoring of driver gene mutation profiles in plasma cfDNA using an 85 gene panel for postoperative prognosis in colorectal cancer.

Tanxiao Huang


Effect of different chemotherapy regimens on pathological response in the preoperative combined chemo radiotherapy of rectal adenocarcinomas: A retrospective analysis.

Rebecca Buecker


Effect of liver metastasis from primary rectal adenocarcinoma on activity of tissue plasminogen activators and α2-macroglobulin.

Elena Alekseevna Dzhenkova


Effect of matched therapy in metastatic colorectal cancer on progression free survival in the phase I setting.

Michael Lam


Effect of PET-CT on disease recurrence and its management in patients with potentially resectable colorectal cancer liver metastases. The long-term results of a randomized controlled trial (PET-CT Imaging prior to liver resection for colorectal adenocarcinoma metastases).

Pablo Emilio Serrano Aybar


Effect of time to resection of colorectal liver metastases on recurrence risk.

Emerson Yu-sheng Chen


Efficacy, tolerability, and manageability of TAS-102 plus bevacizumab for metastatic colorectal cancer patients in clinical practice.

Hideki Ishikawa


Efficiency and safety of regorafenib in metastatic colorectal cancer (mCRC): Real life experience from Turkey.

Guliz Zengin


EGFR protein expression of the metastatic colorectal cancer as a prognostic/predictive factor for anti-EGFR antibody therapy.

Jozsef Timar


ENCORE 601: A phase 2 study of entinostat in combination with pembrolizumab in patients with microsatellite stable metastatic colorectal cancer.

Nilofer Saba Azad


EORTC-ESSO 1409 GITCG: A prospective colorectal liver metastasis database with an integrated quality assurance program (CLIMB).

Carmela Aves Caballero


Ex vivo co-culture models for immunotherapy with patient-derived tumor infiltrating lymphocytes, peripheral blood mononuclear cells and autologous patient colorectal cancer (CRC) cell lines.

Si Qi Tan


Final overall survival (OS) analysis of first-line (1L) FOLFOX-4 ± cetuximab (cet) in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 3 TAILOR trial.

Shukui Qin


Final results of a phase II of metformin plus irinotecan for refractory colorectal cancer.

Arinilda Bragagnoli


First-in-human dose escalation of monalizumab plus durvalumab, with expansion in patients with metastatic microsatellite-stable colorectal cancer.

Neil Howard Segal


First-line FOLFOX plus panitumumab (Pan) followed by 5FU/LV plus Pan or single-agent Pan as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study.

Filippo Pietrantonio


First-line treatment with panitumumab plus FOLFIRI in elderly patients with RAS/BRAF wild-type unresectable metastatic colorectal cancer and good performance status: OPALO trial.

Jaime Feliu


Folate gene prediction of treatment response to 5-FU and leucovorin in advanced colorectal cancer.

Bengt Gustavsson


FOLFIRINOX plus cetuximab (CET) or bevacizumab (BEV) in patients (pts) with initially unresectable colorectal liver metastases (CRLM) with BRAF mutated (mut) tumors: A subgroup analysis of the UNICANCER PRODIGE 14-ACCORD 21 (METHEP2) trial.

Evelyne Lopez-Crapez


Genomic landscape, clinical characteristics and outcomes of early onset (EO) compared with average onset (AO) colorectal cancer (CRC).

Gustavo Dos Santos Fernandes


Genotype-driven dosing of irinotecan and adverse events in patients receiving irinotecan with UGT1A1 gene variants.

Candice Baldeo


Health related quality of life in elderly or frail patients with advanced colorectal cancer treated with dose reduced capecitabine.

Daniel Adam Breadner


High levels of cell-free DNA (cfDNA) at baseline (BL) and increase of at least one mutation at day 14 (D14) as independent prognostic biomarkers for patients (pts) with advanced colorectal cancer (aCRC) under regorafenib.

Pashalina Kehagias


In situ anti-cancer agent derived from [188re]rhenium nitro-imidazole ligand loaded poly-l-lysine dendrimer administrated by direct CT guided stereotactic intrahepatic injection.

Hafid Belhadj-Tahar


Identification for metastasis lymph node in magnetic resonance imaging with faster region-based convolutional neural network.

Yun Lu


Immunological effect of hydrogen gas.

Junji Akagi


Impact of modified Glasgow prognostic score and neutrophil/platelet-lymphocyte ratio on survival metastatic colorectal cancer (mCRC).

Fernando Namuche


Impact of primary tumor side on outcomes of every-2-weeks (q2w) cetuximab + first-line FOLFOX or FOLFIRI in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 2 APEC trial.

Timothy Jay Price


Impact of the type and modalities of preoperative chemotherapy on the outcome of liver resection for colorectal liver metastases: A LiverMetSurvey study.

Yuichi Goto


Implications of KRAS status in first line chemotherapy with bevacizumab in advanced colorectal cancer: A phase IV study of Hellenic Oncology Research Group (HORG).

Anna Koumarianou


Importance of maintenance of dose intensity (DI) during 1st and 2nd line chemotherapy (CT) for nonresectable metastatic colorectal cancer (mCRC).

Mikhail Fedyanin


Induction chemotherapy (CT) with FOLFIRINOX or FOLFOX/FOLFIRI, plus cetuximab (CET) or bevacizumab (BEV) (by RAS status), in patients (pts) with primarily unresectable colorectal liver metastases (CRLM): Results of the randomized UNICANCER PRODIGE 14-ACCORD 21 (METHEP-2) trial.

Marc Ychou


Intensive first line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: Preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers.

Gemma Bruera


Ischemia-induced tumor progression after portal triad clamping in a murine model of colorectal liver metastases: Roles of TNF-a and HO-1.

Desislava Germanova


KEYNOTE-164: Pembrolizumab for patients with advanced microsatellite instability high (MSI-H) colorectal cancer.

Dung T. Le


Long-term results of the ADORE trial: Adjuvant oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX) versus 5-fluorouracil and leucovorin (FL) after preoperative chemoradiotherapy and surgery for locally advanced rectal cancer.

Yong Sang Hong


Maintenance treatment with capecitabine plus cetuximab (CET) for patients with RAS wild-type (wt) advanced colorectal cancer (CRC): A multi-center, phase II clinical trial.

Xianglin Yuan


Meta-analysis of KRAS mutation as prognostic factor in patients (pts.) with resection of colorectal (CRC) liver metastases: Tumor burden and sideness analysis.

Martin Angel


Metastatic colorectal cancer (mCRC) and micro-satellite instability.

Timothy Jay Price


Metastatic site of loss of oncologic control in colorectal cancer patients.

Charles Rajadurai


mFOLFOXIRI + panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer m(CRC): A randomized phase II VOLFI trial of the AIO (AIO- KRK0109).

Michael Geissler


MiR-148a deregulation and colorectal cancer liver metastases.

Jaime Rubio Pérez


Modified FOLFOXIRI regimen as salvage treatment for metastatic colorectal cancer patients: A retrospective study.

Zhen Wang


Multicenter phase I/II trial of BBI608 and pembrolizumab combination in patients with metastatic colorectal cancer (SCOOP Study): EPOC1503.

Eiji Shinozaki


Novel PET/CT imaging biomarkers of CB-839 in combination with panitumumab and irinotecan in patients with metastatic and refractory RAS wildtype (WT) colorectal cancer: A phase I/II study.

Satya Das


NuTide 302: A phase IB study to assess the safety, pharmacokinetics and clinical activity of NUC-3373 in combination with standard agents used in colorectal cancer treatment.

Sarah Patricia Blagden


Optimizing treatment strategy for advanced rectal cancer in the West and Japan: International multicenter cohort study.

Akira Ouchi


Outcomes for matched patients with metastatic colitis-associated cancers versus sporadic colorectal cancer receiving chemotherapy.

Rona Yaeger


Outcomes in left versus right metastatic colorectal cancer (mCRC) in patients presenting to an inner-city safety net hospital.

Sunny R K Singh


Outcomes of cetuximab in 1st-line therapy for metastatic colorectal cancer (mCRC) according to tumor RAS/BRAF mutation (mt) status in the EREBUS cohort.

Denis Michel Smith


Outcomes of oxaliplatin-based (Ox) chemotherapy (CT) on R0 resection of colonic liver metastases (CLM).

Nicholas Adam Bosma


Per protocol analysis and final OS update of the FIRE-3 (AIO KRK-0306) study comparing FOLFIRI plus cetuximab vs. FOLFIRI plus bevacizumab.

Sebastian Stintzing


Phase 2 study of veliparib plus FOLFIRI ± bevacizumab versus placebo plus FOLFIRI ± bevacizumab in metastatic colorectal cancer.

Vera Gorbunova


Physical activity program in patients with metastatic colorectal cancer who receive palliative first-line chemotherapy: A randomized controlled phase III trial—(ACTIVE-2 SAKK 41/14).

Viviane Hess


Plasma HER2 (ERBB2) copy number to predict response to HER2-targeted therapy in metastatic colorectal cancer.

Alberto Bardelli


Possible predictive value of G8 score and the drug concentrations for efficacy and toxicity of trifluridine/tipiracil for elderly patients with advanced colorectal cancer: A multicenter, phase II study (T-CORE1401).

Masanobu Takahashi


Preliminary results from a study of sevacizumab in Chinese patients with metastatic colorectal cancer resistant to oxaliplatin-based first-line chemotherapy.

Nong Xu


Preventive effect of traditional Japanese medicine, syakuyakukanzoto on neurotoxicity of FOLFOX plus bevacizumab for metastatic colorectal cancer: A phase II study.

Hiroaki Takagi


Primary tumor location as a prognostic implication in patients undergoing resection for colorectal liver metastasis: A propensity score-matched analysis.

Yuichi Goto


Prognostic value of neutrophil- (NLR) and platelet-lymphocyte ratio (PLR) in patients with metastatic colorectal cancer (mCRC) with KRAS, BRAF: A Peruvian point of view.

Fernando Namuche


Proteomic profiling of phosphatidylinositol 3-kinase (PI3K) altered metastatic colorectal cancer (mCRC) after protein kinase B (Akt) inhibition: Insulin like growth factor 1 receptor (IGF1R) mediates adaptive resistance.

Maliha Nusrat


Quality-adjusted time without symptoms or toxicity (Q-TWiST) of patients with metastatic colorectal cancer (mCRC) treated with fruquintinib in the randomized phase III FRESCO trial.

Yu-Xian Bai


Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208.

Howard S. Hochster


Ranking the efficacies of FOLFOX and FOLFIRI with or without anti-EGFR therapy or bevacizumab in wild-type-RAS metastatic colorectal cancer according to primary tumor location: A network meta-analysis.

Mingyi Zhou


Real-world data on overall survival (OS) impact of anti-EGFR sequence in patients (pts) with microsatellite stable (MSS) all-RAS and BRAFV600E wild-type metastatic (met) colorectal cancer (CRC).

Elena Elez


Results of a randomized phase 3 study evaluating the potential benefit of a second-look surgery plus HIPEC in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP- NTC01226394).

Diane Goere


REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan—Biomarker analysis.

Yasushi Tsuji


Safety analysis of a phase III randomized trial comparing FOLFOX + Bevacizumab vs FOLFOXIRI + Bevacizumab as 1st line treatment in patients with metastatic colorectal cancer (mCRC) with ≥3 circulating tumor cells (CTCs) (VISNÚ-1 TTD TRIAL).

A. Gomez


Safety and tolerability of the bolus 5-fluorouracil (5-FU) based FLOX and IFL regimens in patients who developed fluoropyrimidine-induced coronary vasospasm during therapy with infusional 5-FU or capecitabine.

Sakti Chakrabarti


Safety of self-expandable metal stents (SEMS) or emergency surgery for acute malignant colonic obstruction in patients treated with bevacizumab.

Vilma Pacheco-Barcia


Salvage use of Y90 coated hepatic arterial beads in the treatment of liver predominant metastatic colorectal cancer: Cancer Treatment Centers of America Southeastern Region experience.

Eyal Meiri


Screening and stepped care targeting psychological distress in patients with metastatic colorectal cancer: The TES cluster randomized trial.

Claudia Schuurhuizen


Significance of monitoring vascular endothelial growth factor signals in blood during treatment of colorectal cancer patients.

Nao Kakizawa


Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO, a randomized, double-blind, phase 3 trial comparing fruquintinib versus placebo plus best supportive care in Chinese patients with metastatic colorectal cancer (mCRC).

Ruihua Xu


Surgical quality and the impact of liver resection on outcome in the New EPOC study.

Sian Alexandra Pugh


The relationship between TACC3 expression and chemotherapy resistance in locally advanced rectal cancer patients.

Rong-xin Zhang


The trough levels of bevacizumab significantly affect the outcome of the treatment in patients with metastatic colorectal cancer: A Turkish Oncology Group study.

Hakan Akbulut


Therapeutic and cytotoxic responses after radiofrequency ablation combined to in situ immunomodulation and PD1 blockade in colorectal cancer.

Katia Lemdani


Treatment of rectal cancer patients with synchronous liver metastases.

Alexey Privalov


Tumor specific methylation of NPY compared to RAS mutation in plasma DNA in the monitoring of colorectal cancer patients treated with last-line regorafenib.

Lars Henrik Jensen


Tumoral cavitation in colorectal cancer patients with lung metastasis treated with bevacizumab and chemotherapy.

Hongfeng Gou


Update survival analysis from a multicenter, randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in patients with metastatic colorectal cancer (mCRC).

Antonio Avallone


Validation of neoadjuvant rectal cancer (NAR) score as a surrogate endpoint for overall survival in real-life practice settings.

Y. Nancy You


What is the prognostic impact of BRAF mutation in patients undergoing resection of colorectal liver metastases? Results of nationwide intergroup (ACHBT, FRENCH, AGEO) cohort of 249 patients.

Jean-Baptiste Bachet